- Condition: Alzheimer´s Disease
Interventions: Biological: Immune Globulin Intravenous (Human), 10% Solution; Biological: Human albumin 0.25%
Sponsors: Baxter Healthcare Corporation; Baxter Healthcare Corporation
Recruiting - verified May 2012 - Condition: Alzheimer's Disease
Interventions: Drug: MABT5102A; Drug: MABT5102A; Drug: placebo; Drug: placebo
Sponsors: Genentech; Genentech
Recruiting - verified August 2011 - Condition: Alzheimer's Disease
Interventions: Drug: AAB-003 (PF-05236812); Drug: AAB-003 (PF-05236812); Drug: AAB-003 (PF-05236812); Drug: AAB-003 (PF-05236812); Drug: AAB-003 (PF-05236812)
Sponsors: Pfizer; Pfizer; JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Recruiting - verified May 2012 - Condition: Dementia Alzheimer's Type
Interventions: Drug: SAR110894D; Drug: placebo
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Condition: Alzheimer's Disease
Interventions: Drug: AAB-003 (PF-05236812); Drug: AAB-003 (PF-05236812); Drug: AAB-003 (PF-05236812); Drug: AAB-003 (PF-05236812); Drug: AAB-003 (PF-05236812); Other: Placebo
Sponsors: Pfizer; Pfizer; JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Recruiting - verified May 2012 - Condition: Alzheimer Disease
Interventions: Drug: bapineuzumab; Drug: bapineuzumab; Drug: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012


